Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 28;8(2):486-497.
doi: 10.31662/jmaj.2024-0243. Epub 2025 Feb 14.

Clinical Information and Prognosis of High-risk Luminal Breast Cancer Subjects Eligible for the MonarhE Study

Mio Adachi  1   2 , Toshiyuki Ishiba  1   2 , Sakiko Maruya  1 , Kumiko Hayashi  1 , Yuichi Kumaki  1 , Goshi Oda  1 , Tomoyuki Aruga  2
Affiliations

Clinical Information and Prognosis of High-risk Luminal Breast Cancer Subjects Eligible for the MonarhE Study

Mio Adachi et al. JMA J. .

Abstract

Introduction: Luminal breast cancer is the most common breast cancer subtype. Although its prognosis can be good, this type of breast cancer is characterized by a high incidence of late recurrence. However, to the best of our knowledge, there are no publications showing prognostic value regarding the invasive-disease-free survival (IDFS) and distant relapse-free survival in this group in clinical practice. Therefore, this study examined the clinical data and prognosis of patients participating in the MonarchE trial.

Methods: This study included patients who underwent surgery at Tokyo Metropolitan Komagome Hospital and whose corresponding prognosis to the Monarch E trial could be followed up.

Results: The total number of participants was 152, of whom 104 (68%) were treated with chemotherapy. Seventy-five patients (49%) were postmenopausal. The IDFS after 5 years was 85.0%. Although IDFS did not differ in terms of the menstrual status, premenopausal patients tended to receive a higher proportion of tamoxifen, and there was a greater number of patients treated with chemotherapy. However, neither chemotherapy nor menstrual statuses were found to affect the IDFS incidence.

Conclusions: Real clinical data applicable to the MonarchE study were examined. Our univariate analysis revealed that there were no factors affecting IDFS.

Keywords: MonarchE; adjuvant therapy; luminal breast cancer.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1.
Figure 1.
Kaplan-Meier Curve of IDFS The IDFS at 5 years was 89.5%. The median was not reached.
Figure 2.
Figure 2.
Kaplan-Meier Curve of DRFS The DRFS at 5 years was 89.0%. The median was not reached.
Figure 3.
Figure 3.
Kaplan-Meier Curve of OS The OS at 5 years was 95.0%. The median was not reached.
Figure 4.
Figure 4.
Comparison of four or more lymph node metastases and the following IDFS The Kaplan-Meier curve of IDFS divided by number of lymph node metastases (p = 0.35, HR: 1.42 [95% CI: 0.68-2.96]).(p = 0.225, HR: 1.57 [95% CI: 0.75 3.25]).
Figure 5.
Figure 5.
Comparison of premenopausal and postmenopausal the following IDFS The Kaplan-Meier curve of IDFS divided by menopause is shown. (p = 0.35, HR: 1.42 [95% CI: 0.68-2.96]).
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. - PubMed
    1. Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer―major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290-303. - PubMed
    1. Tanaka R, Yamagishi Y, Koiwai T, et al. Comparison between AJCC 8th prognostic stage and UICC anatomical stage in patients with primary breast cancer: a single institutional retrospective study. Breast Cancer. 2020;27(6):1114-25. - PMC - PubMed
    1. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736-50. - PMC - PubMed
    1. Howlader N, Cronin KA, Kurian AW, et al. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619-26. - PubMed

LinkOut - more resources